AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis Press release
AAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs Press release
Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing Press release
AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies Press release
Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering Press release
Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin Press release
Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency Press release
Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years Press release
